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The ALPPS Risk Score
Avoiding Futile Use of ALPPS
Michael Linecker, MD, Gregor A. Stavrou, MD,yz Karl J. Oldhafer, MD,yz Robert M. Jenner, MD,y
Burkhardt Seifert, PhD,§ Georg Lurje, MD, Jan Bednarsch, MD, Ulf Neumann, MD,
Ivan Capobianco, MD,jj Silvio Nadalin, MD,jj Ricardo Robles-Campos, MD,
Eduardo de Santiban˜es, MD, PhD, FACS,yy Massimo Malago´, MD,zz Mickael Lesurtel, MD, PhD,
Pierre-Alain Clavien, MD, PhD, FACS, and Henrik Petrowsky, MD, FACS
Objectives: To create a prediction model identifying futile outcome in
ALPPS (Associating Liver Partition and Portal vein ligation for Staged
hepatectomy) before stage 1 and stage 2 surgery.
Background: ALPPS is a 2-stage hepatectomy, which incorporates paren-
chymal transection at stage 1 enabling resection of extensive liver tumors.
One of the major criticisms of ALPPS is the associated high mortality rate up
to 20%.
Methods: Using the International ALPPS Registry, a risk analysis for futile
outcome (defined as 90-day or in-hospital mortality) was performed. Futility
was modeled using multivariate regression analysis and a futility risk score
formula was computed on the basis of the relative size of logistic model
regression coefficients.
Results: Among 528 ALPPS patients from 38 centers, a futile outcome was
observed in 47 patients (9%). The pre-stage 1 model included age 67 years or
older [odds ratio (OR) ¼ 5.7], and tumor entity (OR ¼ 3.8 for biliary tumors)
as independent predictors of futility from multivariate analysis. For the pre-
stage 1 model scores of 0, 1, 2, 3, 4 and 5 were associated with futile risk of
2.7%, 4.9%, 8.6%, 15%, 24%, and 37%. The pre-stage 2 model included
major complications (grade  3b) after stage 1 (OR ¼ 3.4), serum bilirubin
(OR ¼ 4.4), serum creatinine (OR ¼ 5.4), and cumulative pre-stage 1 risk
score (OR ¼ 1.9). The model predicted futility risk of 5%, 10%, 20%, and
50% for patients with scores of 3.9, 4.7, 5.5, and 6.9, respectively.
Conclusions: Both models have an excellent prediction to assess the indi-
vidual risk of futile outcome after ALPPS surgery and can be used to avoid
futile use of ALPPS.
Keywords: ALPPS, associating liver partition and portal vein ligation for
staged hepatectomy, futility, mortality, outcome, risk score
(Ann Surg 2016;xx:xxx–xxx)
ALPPS (Associating Liver Partition and Portal vein Ligation forStaged Hepatectomy)1,2 is a novel variant of 2-stage hepatec-
tomy combining parenchymal transection with portal vein occlusion
at stage 1 resulting in accelerated liver hypertrophy and enabling
completion hepatectomy (stage 2) within a short period of 1 to 2
weeks. Despite these great advantages, ALPPS has been seriously
challenged by criticisms on reported high morbidity and mortality.
Even experienced centers have reported high mortality rates up to
20%.3–7
Although several risk factors for mortality have been ident-
ified,7–10 there are currently no tools available allowing the quanti-
fication of the individual cumulative risk for futile outcome after
ALPPS. Therefore, knowing the individual risk before stage 1 or
stage 2 surgery would help hepatobiliary surgeons to guide better
patient selection and proper surgical treatment to avoid futile use
of ALPPS.
The present study was undertaken to analyze the short-term
outcome of patients undergoing ALPPS to identify pre-stage 1 and
pre-stage 2 risk factors for surgery-related futile outcome, which was
defined as 90-day or in-hospital mortality. The main objective was to
develop 2 prediction models that allow the quantified assessment of
the cumulative risk for futile outcome upfront before stage 1 and
subsequently before stage 2 surgery.
PATIENTS AND METHODS
Study Design
All patients entered in the International ALPPS Registry from
October 2012 to October 2015 were analyzed. The ALPPS Registry
is an international platform with voluntary data entry to collect
worldwide the experience of this procedure with currently counting
more than 200 participating centers. The Registry is coordinated by
the Department of Surgery, University of Zurich, Switzerland using
the Web-based data capture system secuTrial (Interactive System,
Berlin, Germany) which is accessible through www.alpps.net. Data
monitoring was performed by a specialized study nurse and the
coordinator of the ALPPS registry on a weekly basis. The primary
goal of the study was to develop 2 models to predict surgery-related
futile outcome before stage 1 and before stage 2 surgery. Surgery-
related futility was defined as 3-month or in-hospital mortality after
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stage 1 surgery. Ethics approval was obtained from the Cantonal
Ethics Committee Zurich and the Registry was registered at
ClinicalTrials.gov (NCT01924741). The Scientific Committee of
the ALPPS registry approved the present study on March 16,
2015. The data sets of the included patients were exported from
the Registry on September 29, 2015. In addition to these data, high-
volume centers were asked to provide data outside the Registry.
Upon agreement, the data were subsequently incorporated in the
ALPPS Registry.
Inclusion and Exclusion Criteria
All eligible Registry patients were screened for inclusion in
the study. Only ALPPS procedures with complete or partial paren-
chymal transection were included; other transection variants such as
tourniquet- and ablation-assisted ALPPS11,12 were not included.
Furthermore, only centers which reported 5 or more ALPPS cases
were included to minimize the learning effect. Lacking data of the
primary end point and failure to proceed with stage 2 surgery were
further exclusion criteria.
Definitions of Variables and Outcome Measures
The primary end point of the study was surgery-related futile
outcome, which was defined as 90-day or in-hospital mortality
calculated from the date of stage 1 surgery. Liver tumors were
classified into 3 groups: colorectal liver metastases (CRLM), biliary
tumors including cholangiocarcinoma and gallbladder cancer, and
noncolorectal/nonbiliary tumors. The Charlson Comorbidity Index
was recorded as global measure of comorbidities.13 Cardiovascular
disease (CVD) was defined as one of the following parameters
captured in the registry: congestive heart failure, history of myo-
cardial infarction, medical treatment including antianginal agents,
aspirin, digoxin, antihypertensives, or other cardiovascular drugs.
Complications after ALPPS were recorded using the Clavien-Dindo
classification.14 Major complications were defined as grade 3b or
higher.14 To assess liver failure, 2 commonly used criteria were
applied before and after stage 1 surgery: Model of End-stage Liver
Disease (MELD)15 and the International Study Group of Liver
Surgery (ISGLS) criteria.16 Further outcome variables included
interstage liver function performance, future liver remnant (FLR)
growth, and length of intensive care unit and hospital stay.
Statistical Methods
Descriptive Statistics
Continuous data were expressed as median and interquartile
range, categorical data as absolute numbers and percentage. P values
for comparing outcomes between futile and nonfutile groups were
computed using the x2 test for categorical variables and the Mann-
WhitneyU test for continuous variables. P values less than 0.05 were
considered statistically significant.
Multivariate Regression Analysis
All variables, which proofed to be statistically significant in
the univariate analysis and had a data completion rate of at least 70%,
were considered for multivariate regression analysis (Tables 1 and 2).
Regression analysis was separately performed for pre-stage 1 and for
pre-stage 2 data to identify risk factors in a pre-stage 1 and pre-stage
2 model. Based on discussion between clinician and biostatistician,
TABLE 1. Pre-stage 1 Characteristics
Variable Data Completion, % Futile (n ¼ 47) Nonfutile (n ¼ 481) P
Age, yr 95 69 (64–74) 61 (52–68) <0.001
Sex; male, n, % 100 30 (64) 273 (57) 0.397
BMI, kg/m2 94 26 (23–29) 25 (23–28) 0.481
Liver tumor 95
CRLM, n, % 19 (41) 324 (71) <0.001
Biliary tumors, n, % 18 (39) 58 (13) <0.001
Non-CRLM/nonbiliary, n, % 9 (20) 69 (15) 0.401
Chemotherapy, n, % 93 20 (44) 313 (70) <0.001
Comorbidities§
Charlson Comorbidity Index 92 6 (2–6) 6 (6–6) 0.068
Age-adjusted Charlson Comorbidity Index 89 7 (5–9) 7 (6–8) 0.878
CVD, n, % 100 10 (21) 41 (9) 0.009
Renal disease, n, % 100 3 (6) 7 (1) 0.051
Diabetes mellitus, n, % 100 8 (17) 44 (9) 0.117
COPD, n, % 100 3 (6) 16 (3) 0.234
Abdominal surgery, n, % 100 12 (26) 229 (47) 0.003
Liver baseline characteristics
FLR/BW pre-stage 1 82 0.33 (0.29–0.41) 0.35 (0.27–0.46) 0.375
sFLR pre-stage 1 85 0.19 (0.16–0.24) 0.21 (0.16–0.28) 0.182
Macrosteatosis, n, % 42 10 (44) 64 (32) 0.351
Fibrosis, n, % 44 6 (26) 52 (25) 1.000
Steatohepatitis, n, % 46 6 (27) 39 (18) 0.261
CASH, n, % 41 5 (26) 40 (20) 0.554
Bilirubin, mg/dL 84 0.70 (0.41–1.58) 0.59 (0.40–0.82) 0.011
INR 79 1.00 (0.99–1.10) 1.00 (0.95–1.10) 0.331
Creatinine, mg/dL 74 0.83 (0.70–1.00) 0.80 (0.70–0.92) 0.336
MELD score 66 7 (6–10) 6 (6–7) 0.054
Categorical variables presented as count and percentage (%), continous variables presented as median and interquartile range (IQR).
History of previous major abdominal surgery.
§Comorbidities not mentioned were assumed not exisiting.
BMI indicates body mass index; CASH, chemotherapy-associated steatohepatitis; COPD, chronic obstructive pulmonary disease; BW, bodyweight; INR, international normalized
ratio; sFLR, standardized FLR.
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only clinically useful parameters for decision making were finally
included in the stepwise analysis purposely avoiding automatic
variable selection. ‘‘CRLM’’ and ‘‘chemotherapy before stage 1’’
would be an example of 2 variables formally fulfilling the criteria but
only CRLM were considered for multivariate analysis due to the
clinical association of both variables. Since all CRLM underwent
preoperative chemotherapy we wanted to avoid a false conclusion
that chemotherapy itself is protective. Table 3 displays the respective
logistic regression coefficients and odds ratios (ORs) with 95%
confidence intervals (CIs) of pre-stage 1 and pre-stage 2 variables.
Calibration of both regression models was assessed using the
Hosmer-Lemeshow test.
Modeling Futile Outcome
Futility was modeled as function of identified risk factors in
the multivariate regression analysis. Having 47 futile events from a
total population of 528 patients, we aimed to study a maximum of
4 to 5 variables to prevent overfitting of the model as it is recom-
mended in the 1-in-10 rule.17
A nonparametric receiver operating characteristic (ROC)
analysis using the logit scores from the pre-stage 1 and pre-stage
2 final model was performed. The concordance (c) statistics was
calculated as measure of model performance. For clinical practic-
ability, cut-off variables were preferred over continuous variables. In
this model cut-offs were, however, only used when the c-statistic was
not inferior compared with the continuous alternative. The determi-
nation of the optimal cut-off value of continuous covariates (eg, age)
was performed using ROC analysis and accuracy plots.18 An ALPPS
risk score formula for futile outcome was computed on the basis of
the relative sizes of logistic regression coefficients (Table 3). In
addition, we were interested if ISGLS liver failure at postoperative
day (POD) 5 and complications 3b or higher are associated with the
pre-stage 1 score before surgery.
All statistical analyses were performed using IBM SPSS
Statistics version 22 forMacintosh (IBMCorporation, Armonk, NY).
RESULTS
Study Population
A total of 640 registered patients from 102 centers were
screened to be included in the study. Of these 640, 146 patients
(23%) were excluded due to various exclusion criteria such as centers
reported less than 5 cases (n¼ 83), other ALPPS transection variants
(n ¼ 52), and failure to proceed with stage 2 (n ¼ 11). Two centers
outside the registry provided additional 34 patients with complete
data sets. Finally, the study population was composed of 528 patients
from 38 centers (Supplemental Fig. 1, http://links.lww.com/SLA/
B60). The majority of ALPPS cases was performed for CRLM (69%)
followed by 16% of cases for noncolorectal/nonbiliary and 15% for
biliary tumors.
TABLE 2. Pre-stage 2 Characteristics
Variable Data Completion, % Futile (n ¼ 47) Nonfutile (n ¼ 481) P
Characteristics of stage 1
Partial ALPPS, n, % 100 2 (4) 43 (9) 0.411
Use of Pringle, n, % 99 16 (35) 125 (29) 0.225
CVP, mmHg 53 5 (3–6) 5 (4–6) 0.331
Transfusion, n, % 95 15 (32) 99 (22) 0.142
Overall complications, n, % 77 27 (60) 102 (28) <0.001
Major complications, n, % 85 15 (33) 30 (7) <0.001
Dialysis after stage 1, n, % 10 9 (100) 3 (7) <0.001
Operation time stage 1, min 82 341 (270–490) 300 (250–385) 0.026
ICU stay after stage 1, days 69 4 (1–9) 1 (1–3) <0.001
Hospital stay after stage 1, days 81 12 (9–18) 10 (7–13) 0.003
Interstage liver performance
Liver volume characteristics
FLR/BW pre-stage 2 80 0.59 (0.46–0.74) 0.62 (0.51–0.75) 0.139
sFLR pre-stage 2 77 0.33 (0.27–0.44) 0.40 (0.33–0.47) 0.006
D sFLRy 73 0.14 (0.08–0.20) 0.16 (0.11–0.22) 0.127
sFLR increase, % 66 77 (52–105) 70 (46–106) 0.615
Liver tests at POD 5
Serum bilirubin, mg/dL 84 1.13 (0.77–4.05) 0.80 (0.50–1.33) <0.001
INR 81 1.20 (1.10–1.47) 1.10 (1.00–1.21) 0.008
Serum creatinine, mg/dL 74 1.06 (0.71–1.85) 0.70 (0.59–0.86) <0.001
MELD score 66 11 (8–20) 8 (7–10) <0.001
ISGLS, n, % 83 10 (23) 36 (9) 0.015
Liver tests pre-stage 2
Serum bilirubin, mg/dL 82 1.40 (0.70–3.93) 0.70 (0.41–1.20) <0.001
INR 79 1.20 (1.09–1.36) 1.10 (1.00–1.20) 0.036
Serum creatinine, mg/dL 73 1.01 (0.70–1.63) 0.70 (0.60–0.86) <0.001
MELD score 64 9 (7–13) 8 (7–10) 0.081
ISGLS, n, % 79 4 (10) 35 (9) 0.780
Interstage interval, d 74 11 (8–14) 10 (8–14) 0.856
Stage 2 surgery
Operation time, min 68 165 (140–215) 144 (110–200) 0.051
Concomitant resections, n, % 100 3 (6) 18 (4) 0.420
Categorical variables presented as count and percentage (%), continous variables presented as median and interquartile range (IQR).
Defined as complications 3b; sFLR, standardized future liver remnant.
yAbsolute change of sFLR volume before and after stage 1 surgery.
CVP indicates central venous pressure; BW, body weight; ICU, intensive care unit; INR, international normalized ratio.
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Peri- and Postoperative Outcome
The median operation time of stage 1 and 2 surgery was 305
(250–393min) and 150 minutes (112–200min). The major compli-
cation rate (grade 3b) and total complication rate after stage 1
surgery was 10% and 32%, respectively. Themedian volume increase
of standardized FLR between stages was 70% (46%–106%).
Approximately 11% of patients developed liver failure at POD 5
according to the ISGLS criteria. Stage 2 surgery was performed after
a median interstage interval of 10 days (8–14 d) and the reported 90-
day or in-hospital mortality rate was 9%.
Futile Versus Nonfutile Outcome
Among the 528 patients, 47 patients (9%) had a futile outcome
after ALPPS surgery, with 18 patients (38%) and 45 patients (96%)
dead at 1 and 3 months, 2 patients died in hospital after 3 months.
Patients with futile outcome were in median 8 years older (69 vs
61 yr), had a higher proportion with CVD (21% vs 9%) and under-
went less frequently resection for CRLM (41% vs 71%) than non-
futile cases (Table 1). Patients with a futile outcome experienced
more frequently major postoperative complications after stage 1
surgery (33% vs 7%) and had a higher incidence of ISGLS-defined
liver failure at POD 5 (23% vs 9%) (Table 2). The leading cause of
death in the futile groups was septic shock in 18 patients (38%)
followed by liver failure in 17 patients (36%), cardiogenic shock in
5 patients (11%), and other causes of death in 7 patients (15%).
Pre-stage 1 Prediction Model of Futile Outcome
The pre-stage 1 multivariate analysis identified age and biliary
tumors as independent pre-stage 1 predictors for futility with the
greatest risk from age 67 years or older (OR ¼ 5.67; 95% CI 2.84–
11.3), and biliary tumors (OR ¼ 3.77; 95% CI 1.80–7.88) (Table 3).
The calibration of the model was assessed by the Hosmer-Lemeshow
test (P ¼ 0.235). CVD marginally failed statistical significance (P ¼
0.075). ROC analysis and accuracy plot revealed age of 67 years
as optimal age cut-off value for predicting futility (Fig. 1A, B). Age
as continuous variable had no advantage over using the age cut-off of
67 years in predicting futility (c-statistic 0.771 vs 0.772). Using all
3 independent predictors, the futility prediction of the pre-stage 1
model had a c-statistic of 0.772 (95% CI 0.695–0.850) (Fig. 1C). A
futility pre-stage 1 score was created on a 0 to 5 scale predicting
futility risk of 2.7%, 4.9%, 8.6%, 15%, 24%, and 37% for patients
with scores of 0, 1, 2, 3, 4, and 5, respectively (Table 3, Fig. 1D).
There was a significant association of pre-stage 1 futility score and
the probability of ISGLS liver failure at POD 5 (P¼ 0.016) and post-
stage 1 complications 3b or higher (P ¼ 0.006).
Pre-stage 2 Prediction Model of Futile Outcome
The pre-stage 2 multivariate analysis identified pre-stage 1
score (OR¼ 1.92; 95%CI 1.53–2.43), interstage complication grade
3b or higher (OR ¼ 3.4; 95% CI 1.28–8.77), pre-stage 2 serum
bilirubin (OR ¼ 4.4; 95% CI 1.70–11.6), and creatinine (OR ¼ 5.5;
95% CI 1.61–18.5), as independent pre-stage 2 predictors for futility
with a Hosmer-Lemeshow calibration of P ¼ 0.909 (Table 3). Using
all 4 independent predictors, the futility prediction of the model had a
c-statistic of 0.850 (95% CI 0.776–0.924) (Fig. 2A). The model
predicted futility risk of 5%, 10%, 20%, and 50% for patients with
scores of 3.9, 4.7, 5.5, and 6.9, respectively (Table 3, Fig. 2B).
DISCUSSION
The study identified age 67 years or older, biliary liver tumors,
interstage occurrence of major complications, and elevated serum
bilirubin or creatinine before stage 2 as independent predictors of
futile outcome after ALPPS. When these predictors were integrated
in a model predicting futile outcome after ALPPS, the discriminatory
model performance was acceptable for the pre-stage 1 and good for
the pre-stage 2 model. Both models provide statistical tools estimat-
ing the individual futile risk upfront stage 1 and before stage 2
surgery, which may assist the selection process whether and when to
proceed with ALPPS surgery.
ALPPS is associated with many advantages in liver surgery
but early mortality remains a serious problem for this newly practiced
surgical technique. Even experienced hepatobiliary centers have
reported high 90-day mortality rates ranging between 10% and
20%.3–7 To avoid futile use of ALPPS, the main goal of the study
TABLE 3. Risk Modeling
Risk Points Regression Coefficient Odds Ratio (95% CI) P
Pre-stage 1 variables
Tumor typey
CRLM (reference) 0 0.000 1.000
Non-CRLM/nonbiliary 1 0.655 1.925 (0.808–4.585) 0.139
Biliary 2 1.326 3.767 (1.800–7.882) <0.001
Age 67 yr 3 1.735 5.668 (2.843–11.30) <0.001
Intercept pre-stage 1 5.3
Pre-stage 2 variablesz
Pre-stage 1 score, per point 0.66 0.665 1.925 (1.527–2.426) <0.001
Interstage complications 3b 1.2 1.209 3.350 (1.280–8.769) 0.014
Pre-stage 2 bilirubin§ 1.5 1.496 4.439 (1.699–11.60) 0.002
Pre-stage 2 creatininejj 1.7 1.696 5.454 (1.606–18.52) 0.007
Intercept pre-stage 2 6.8
Pre-stage 1 risk score (range 0–5).
yTumor type was classified into CRLM, biliary tumors, and non-CRLM/nonbiliary tumors with CRLM serving as reference. Scores of 0, 1, 2, 3, 4, and 5 were associated with futile
risk of 2.7%, 4.9%, 8.6%, 15%, 24%, and 37%, respectively.
zPre-stage 2 risk score (range 0–12). Pre-stage 2 score¼ 0.66 (pre-stage 1 score)þ 1.2 (1¼ complications3b; 0¼ complications3b)þ 1.5 log10 (10 bilirubin pre-stage
2 in mg/dL)þ 1.7 log10 (10 creatinine pre-stage 2 in mg/dL). Predicted pre-stage 2 futility risk is calculated according to following formula: Futility risk¼ odds/(1þ odds) with
odds¼ exp (6.9þ pre-stage 2 risk score).
§1.5 log10 (10 bilirubin pre-stage 2 in mg/dL).
jj1.7 log10 (10 creatinine pre-stage 2 in mg/dL).
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was to develop 2 prediction models, which would allow estimating
the individual futile risks of patients before undergoing stage 1 and
stage 2 surgery. In general, medical futility can be understood
as treatment that extends life without providing quality of life or
meaningful survival.19 On the basis of this principle, we defined
surgery-related futility when a patient did not reach a survival of
3 months or deceased during the postoperative course regardless of
length of hospitalization. Cancer-related futility was not the objective
of the present analysis and was not considered in the study.
Age greater than 60 years has been repeatedly reported as risk
factor for mortality after ALPPS.8,9,20 In the present study, ROC and
accuracy analysis identified age of 67 years as optimal cut-off for
predicting futility. The reason for this discrepancy of age cut-offs
might be related to the fact that previous studies8–10 did not use
statistical methods to look for the optimal cut-off point. The previous
recommendation of age-related risk20 needs to be revised because
patients within the age segment of 60 to 67 years, which account for
almost one-fourth of the study population (Fig. 1A), would be labeled
with an incorrectly higher risk.
The study confirms previous findings that patients with
CRLM have the lowest futile risk but identified biliary tumors
carrying the greatest risk among all tumor types. Furthermore, the
regression analysis identified the interstage occurrence of major
complications and impaired renal and hepatic function before stage
2 surgery as additional independent predictors of futile outcome. The
clinical effect of the interstage course on early mortality has been
independently shown by previous studies.7,8 Interestingly, measures
of FLR volume and relative hypertrophy had no predictive ability in
assessing futile risk in the present analysis.
The central part of the present study was to develop a risk
model to estimate the likelihood of futile outcome before stage 1 and
stage 2 surgery. When futility was modeled using the predictors age
67 years or older and tumor type, the pre-stage 1 risk model had an
acceptable discriminatory ability with a c-statistic of 0.78. The use of
age as continuous variable and the addition of CVD did not increase
pre-stage 1 model performance. The pre-stage 2 model, which was
based on the predictors pre-stage 1 score, inter-stage major compli-
cations and serum bilirubin and creatinine, had statistically superior
performance over pre-stage 1 prediction with a c-statistic of 0.85.
Models with c-statistics greater than 0.70 are considered clinically
acceptable and greater than 0.80 are associated with good prediction.
Values greater than 0.90 are rarely observed. Therefore, both risk
models especially the pre-stage 2 model have a good performance in
predicting futile risk in ALPPS. For reference, the commonly used
risk assessment tool for estimating the 10-year risk of having a heart
attack (Framingham Heart Study) had a c-statistic from 0.69 to 0.77,
depending on the variables.21
Of note, the pre-stage 1 model presents a static risk score,
whereas the pre-stage 2 score has a dynamic quality due to its
modifiers serum bilirubin and creatinine. The applicability of both
FIGURE 1. Pre-stage 1 prediction model
of futile outcome. Percentage of patients
experiencing futile outcome are plotted
in age groups and show a marked
increase beyond the age of 67 years
(A). The accuracy plot over age as con-
tinuous variable identifies age of 67 years
as optimal cut-off for predicting futility
(B). C, ROC curves of single predictors of
the pre-stage 1 model in comparison
with pre-stage 1 prediction model
(c-statistic 0.772; 95% CI 0.695–
0.850). The pre-stage 1 model was com-
posed of 2 predictors: age 67 years or
older (c-statistic 0.723) and tumor entity
(colorectal, biliary, noncolorectal/non-
biliary). Modeling futility risk based on
the pre-stage 1 cumulative risk score is
illustrated in (D). The futility risk score is
calculated according to the following
formula: pre-stage 1 score¼points age
(0¼<67; 3¼67 years)þpoints tumor
(0¼ colorectal; 1¼non-colorectal/non-
biliary; 2¼biliary).
A B
C D
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risk models is demonstrated in Supplemental Table 1 (http://links.
lww.com/SLA/B60), which displays clinical sample vignettes of
5 patients from the ALPPS registry. The example of the patient
scenario in Figure 2B, however, demonstrates that even a normal-
ization of the modifiers serum bilirubin and creatinine does not shift
the elevated pre-stage 1 risk in a range to proceed safely with stage 2
surgery. Therefore, the previous recommendation that MELD scores
less than 10 are the decision maker to proceed with stage 2 surgery
needs to be reconsidered especially in patients with high pre-stage 1
futile risk.8 The inclusion of composite variables such as MELD,15
ISGLS,16 and 50 to 50 criteria22 into the model was avoided since
these variables did not improve the predictive ability and are more
susceptible for data incompleteness because more than 1 parameter
are used.
The strength of the present study is related to the large sample
size of 528 pooled patients from 38 centers. To reduce potential bias,
we included only centers, which reported 5 or more cases to the
registry. Another important advantage is that the primary endpoint of
90-day mortality presents a robust variable, which is reported by the
vast majority of centers and does not require long-term follow-up. In
contrast, the present study is also associated with certain inherent
shortcomings, which are linked to a registry-based study design with
higher degree of incomplete data sets. When data were initially
retrieved from the registry, centers with higher degree of incomplete
data were identified and contacted to provide missing data of
important demographic and outcome variables. Another criticism
of the registry study is the underreporting of negative events includ-
ing early mortality. The observed 90-day mortality rate of 9% in the
present series might not present the actual mortality figure of this
procedure due to the potential bias of underreporting negative events
to a registry-based database.23,24 We therefore contacted centers in
and outside the registry to report cases with futile outcome. By this
approach, the initial events of futile outcome of 35 cases could be
increased to 47 in the final study population. The greater sample size
of futile events was of central importance for the study due to
approaching a more solid statistical analysis.17
In conclusion, both risk models provide a mathematical tool to
estimate the individual futile risk upfront ALPPS and before stage 2
surgery with a good discriminatory ability. These methods should not
replace clinicians’ best judgment, but might complementary assist
proper patient selection and optimal determination whether and when
to proceed safely with stage 2 surgery.
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B
FIGURE 2. Pre-stage 2 prediction model of futile outcome.
A, ROC curves of single predictors of the pre-stage -2 model
in comparison with pre-stage 2 prediction model (c-statistic
0.850 (95% CI 0.776–0.924)). The pre-stage 2 model was
composed of 4 predictors: pre-stage 1 score (c-statistic 0.772),
post-stage 1 complication 3b (c-statistic 0.612), and pre-
stage 2 serum bilirubin (c-statistic 0.690) and creatinine
(c-statistic 0.726). Modeling futility risk based on the pre-stage
2 cumulative risk score is illustrated in (B). The futility risk
score is calculated according to the following formula:
pre-stage 2 score ¼ 0.66 (pre-stage 1 score)þ1.7 log10
(10 creatinine mg/dL)þ1.5 log10(10bilirubin mg/dL)þ
1.2 (1¼ complication 3b; 0¼ complication <3b). The pre-
dicted pre-stage 2 futility risk is calculated according to follow-
ing formula: futility risk¼odds/(1þodds) with odds¼ exp-
(–6.9þpre-stage 2 score). The squares on the futility risk curve
represent patients #2 from Supplemental Table 1, http://links.
lww.com/SLA/B60. The solid black square presents the actual
risk, whereas the solid red squares present 2 scenarios of patient
#2 with normalization of pre-stage 2 serum bilirubin (1mg/dL)
in scenario 1 and uneventful interstage course with normal
renal (creatinine 1mg/dL) and liver (bilirubin 1mg/dL) func-
tion before stage 2 surgery in scenario 2.
Linecker et al Annals of Surgery  Volume XX, Number X, Month 2016
6 | www.annalsofsurgery.com  2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: A.U.; ANNSURG-D-16-00200; Total nos of Pages: 9;
ANNSURG-D-16-00200
REFERENCES
1. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation
combined with in situ splitting induces rapid left lateral liver lobe hypertrophy
enabling 2-staged extended right hepatic resection in small-for-size settings.
Ann Surg. 2012;255:405–414.
2. De Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver
failure: the ‘‘ALPPS’’ approach. Ann Surg. 2012;255:415–417.
3. Li J, Girotti P, Konigsrainer I, et al. ALPPS in right trisectionectomy: a
safe procedure to avoid postoperative liver failure? J Gastrointest Surg.
2013;17:956–961.
4. Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of
complete resection in patients with primarily unresectable liver tumors
compared with conventional-staged hepatectomies: results of a multicenter
analysis. World J Surg. 2014;38:1510–1519.
5. Nadalin S, Capobianco I, Li J, et al. Indications and limits for associating liver
partition and portal vein ligation for staged hepatectomy (ALPPS). Lessons
Learned from 15 cases at a single centre. Z Gastroenterol. 2014;52:35–42.
6. Kremer M, Manzini G, Hristov B, et al. Impact of neoadjuvant chemotherapy
on hypertrophy of the future liver remnant after associating liver partition and
portal vein ligation for staged hepatectomy. J Am Coll Surg. 2015;221:717–
728.
7. Truant S, Scatton O, Dokmak S, et al. Associating liver partition and portal
vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages
course on morbi-mortality and implications for management. Eur J Surg
Oncol. 2015;41:674–682.
8. Schadde E, Raptis DA, Schnitzbauer AA, et al. Prediction of mortality after
ALPPS stage-1: an analysis of 320 patients from the international ALPPS
registry. Ann Surg. 2015;262:780–786.
9. Schadde E, Ardiles V, Robles-Campos R, et al. Early survival and safety of
ALPPS: first report of the International ALPPS Registry. Ann Surg.
2014;260:829–836.
10. D’Haese JG, Neumann J, Weniger M, et al. Should ALPPS be used for liver
resection in intermediate-stage HCC? Ann Surg Oncol. 2015;23:1335–1343.
11. Linecker M, Kron P, Lang H, et al. Too many languages in the ALPPS:
preventing another tower of Babel? Ann Surg. 2016;263:837–838.
12. Edmondson MJ, Sodergren MH, Pucher PH, et al. Variations and adaptations
of associated liver partition and portal vein ligation for staged hepatectomy
(ALPPS): many routes to the summit. Surgery. 2016;159:1058–1072.
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40:373–383.
14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications:
a new proposal with evaluation in a cohort of 6336 patients and results of a
survey. Ann Surg. 2004;240:205–213.
15. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival
in patients undergoing transjugular intrahepatic portosystemic shunts.
Hepatology. 2000;31:864–871.
16. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a
definition and grading by the International Study Group of Liver Surgery
(ISGLS). Surgery. 2011;149:713–724.
17. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of
events per variable in logistic regression analysis. J Clin Epidemiol.
1996;49:1373–1379.
18. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its
associated cutoff point. Biom J. 2005;47:458–472.
19. Helft PR, Siegler M, Lantos J. The rise and fall of the futility movement. N
Engl J Med. 2000;343:293–296.
20. Oldhafer KJ, Stavrou GA, Van Gulik TM, et al. ALPPS-where do we stand,
where do we go?: eight recommendations from the first international expert
meeting. Ann Surg. 2016;263:839–841.
21. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart
disease using risk factor categories. Circulation. 1998;97:1837–1847.
22. Balzan S, Belghiti J, Farges O, et al. The ‘‘50-50 criteria’’ on postoperative day
5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg.
2005;242:824–828.
23. Dahl T, Rudjord K, Altreuther M, et al. Data quality of surgery for carotid
artery stenosis. Are the national vascular registries reliable? Eur J Vasc
Endovasc Surg. 2006;31:381–385.
24. Clavien PA, Puhan MA. Biased reporting in surgery. Br J Surg. 2014;101:
591–592.
DISCUSSANTS
F. Pruvot (Lille, France):
Congratulations, the term ‘‘futility score’’ is inadequate and
‘‘risk-score’’ seems better. The risk of dying, in your article, range
from 4.7% to 39% for the pre-stage 1 score and from 5% to 50% for
pre-stage 2 score. Beyond which number do you think that ALPPS is
‘‘futile,’’ that is to say too risky or unnecessary?
We showed in Lille (EJSO 2015) that interstage course was as
much important as was pre-stage 1 selection. But if the pre-stage 1
score may avoid a too risky procedure, the pre-stage 2 score may only
help us to modulate the interstage course of patients. So, is the pre-
stage 2 score only useful to postpone the stage 2? Do you think we
can voluntarily abort the procedure? How behaved the 11 patients not
having the stage 2 performed?
Interestingly, neither the baseline of the RLV nor its hyper-
trophy after stage 1 were predictive of mortality. Do you think that
functional assessment using for instance hepatobiliary iminodiacetic
acid (HIDA) scintigraphy may be particularly worth in firstly
selecting good candidates for ALPPS (before stage 1) and secondly
determining the best time point to perform the ALPPS stage 2?
According to my first reviewing, you listed some of the
complications3b after stage 1: biliary complications (15%), bleed-
ing (13%), infection (6%). Did these local complications require re-
intervention? Otherwise they could not be graded as 3b. Moreover,
renal failure (27%) was the leading cause of severe interstage
complications; thus, are the 2 variables ‘‘major complications after
stage 1’’ and ‘‘creatinine levels’’ included in the pre-stage 2,
strictly independent?
Modeling pre-stage 2 score, MELD and ISGLS were not
contributive. Why didn’t you try the 50/50 criteria?
Not distinguishing between the developmental period of
ALPPS and the more recent period, in which technical improvements
have been made, may be a major concern in the present study. Would
reanalyzing the series with the more recent patients avoiding the
complications of the learning curve, give another profile for the pre-
stage 2 score?
Considering the number of events, the number of statistically
significant variables, and the size of the cohort, shouldn’t the authors
try to use the Bootstrap method to enhance the robustness of their
demonstration rather than wait another validation cohort that will
take a long time to set up?
Response From H. Petrowsky (Zurich, Switzerland):
Thank you Dr Pruvot for your challenging and important
questions. I will answer your questions sequentially.
Your first comment targets the question at which cut-off is
ALPPS futile or too risky and should not be performed. The risk
score is not an absolute recommendation of specific figures. The
score should help patients and physicians to estimate the risk before
stage 1 and stage 2 surgery. Both parties, patients and physicians,
have to decide how much risk they want to take. Everybody in the
auditorium would probably agree that a pre-stage 2 risk of 80%
would permit proceeding to stage 2 surgery.
In your second question, you asked whether the pre-stage 2
score is only useful to postpone stage 2. As I pointed out in the
presentation, the pre-stage 2 score can be used not only to postpone
but also to deny stage 2 surgery, if the risk constellation is extra-
ordinary high. I also want to emphasize again that previous recom-
mendations, in which you just have to wait with stage 2 surgery until
the liver function will be normalized, are not true for every case as I
have shown in the clinical vignette that an extraordinary high risk
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might be only marginally decreased by normalization of bilirubin
and creatinine.
In terms of your third question, I agree with you that volume
and hypertrophy were not predictive for mortality. Although the
standardized future liver remnant was significantly lower in the futile
group, it did not come out as independent predictor in the multi-
variate analysis. It might be that liver function is more important in
predicting mortality than volume or hypertrophy. If this is true
then liver function assessment by HIDA scan, as you pointed out,
would be probably very helpful to reliably identify good candidates
for ALPPS.
You also asked whether all major interstage complications
required interventions? All complications graded as 3b or higher
required intervention or intensive care unit management. We cannot
exclude that renal failure as major complication has some minor
degree of interaction with the risk factor creatinine but we think that
this can be neglected because only one fourth of major complications
are related to renal problems, and in addition, the risk factor
creatinine reflects the pre-stage 2 renal function rather than the
interstage course of creatinine.
Next, you asked why we did not try to use the 50–50 criteria?
Indeed we did but the numbers of patients fulfilling the 50–50
criteria were very low that the inclusion of these criteria did not make
sense from the statistical point of view.
Your question of the learning curve is a very important
question. In general, the learning curve of a procedure or intervention
can apply to technical improvements of the procedure itself or to
selection and indication. We agree with you that technical improve-
ments in ALPPS might have some effects on the learning curve, but
more importantly we think that the learning curve in ALPPS is
mainly associated with a modified selection of patients which are
probably the main bulk of this analysis. But, to address the technical
learning curve issue we included in our analysis only centers which
entered at least 5 ALPPS cases in the registry.
In terms of your last question, we agree with you that boot-
strapping could be another method to go. The main reason why we
did not perform bootstrapping as internal validation method was that
our goal was to validate the model externally in a future population of
ALPPS cases entered in the registry.
C. Bruns (Cologne, Germany):
Last year, your group and others presented as far as I remem-
ber around 320 patients with also the idea to predict those patients
who are not able to pass from stage 1 to stage 2. The final article,
which was published in the November issue from last year, said that
there definitely are some patients who should have no stage 2 and
should be delayed or denied. We have to accept that ALPPS should
bemade safer. Themortality in that article, I think was approximately
8%, but that included those centers with less than 5 procedures. Now
you have them excluded and we still end up with 9%mortality. That’s
my first question-please comment on this.
The second question is, in the last article there were already
evaluated theMELD score, bilirubin, the age, and cardiac co-morbid-
ity and the tumor entity. What is now the difference because that was
in my opinion also a sort of prediction score? Could you comment
on this?
Response From H. Petrowsky (Zurich, Switzerland):
Thank you for your important comments. I will start to answer
the last question. Indeed, the study from last year showed some risk
factors but it did not provide the cumulative risk of an individual
patient scenario. The current project presents a further development
of a pure regression analysis. What does it mean if the patient is
older than 67 years and has a biliary tumor? Yes, the risk is elevated
but we want to know the cumulative risk. In terms of data quality,
we did a lot of efforts to improve the data completeness and quality.
The article you mentioned from last year had 28 futile events, and in
the present study 47. The previous article had a total of 320 patients;
they present a total of 528 patients. Therefore, data quality
and statistical analysis are more solid compared to the previous
article.
Addressing you first question, yes it is true that the mortality is
still 9%. The 2 centers that we contacted outside the registry were
centers where we knew they had futile outcome. The problem with
mortality is underreporting. Centers have a trend to report only good
outcome and therefore we made every effort to include more futile
events. Our goal was not primarily to increase the total number of the
study population, but more importantly to increase the number of
negative events with futile outcome to have a more solid
statistical analysis.
R. Adam (Villejuif, France):
A first comment: You built a model of futility, and you exclude
11 patients who did not reach the second operation. By definition for
me, not to reach the second operation is the best sign of futility. Thus,
your model should take into account the 11 patients who did not
reach the second stage.
My question concerns the clinical application of your risk
assessment.What do you think could be the cut off for which you will
decide to proceed or not to the second stage? Do you think that you
will have a confrontation with the opinion of the oncologist for a
chemotherapy that may help? Because of course, what do you do
with a risk of 50%? Do you proceed or not?
Response From H. Petrowsky (Zurich, Switzerland):
Dr Adam, thank you for your critical comments and questions.
Your first question was just addressed before. I agree that this could
probably fit into the futility concept but just to have 11 patients
represents a significant selection bias due to underreporting. I really
recommend doing a study looking at patients who did not reach stage
2; however, this cannot be done by just the 11 patients reported to
the registry.
Your second question targets the 50% risk. Yes, it is difficult
but at the end, like in every other cancer surgery, you have to come up
with a consent with your patient and your team including oncologists.
What you also have to consider is that every prediction model has a
predicting probability. For the pre-stage 2 model, the c-statistics was
0.85. This means that your prediction is correct in 85% but not
in 15%. These numbers, compared to other prediction models,
however, have a very good model performance. I think, at the end
the prediction models might assist patient selection and make
ALPPS safer.
T. van Gulik (Amsterdam, The Netherlands):
It will be extremely valuable to assess patients after stage 1
and be able to predict outcome after stage 2. What I missed is the
kinetic growth rate of the remnant liver calculated after stage 1. This
is an important indicator of the hypertrophy response. I did not see
how you handled kinetic growth rate in your analysis.
Next, we have seen an evolution in the technical aspects of
ALPPS. One of the things which certainly have decreased the
operative risk is by performing a partial ALPPS at stage 1. How
did you deal with this technical evolution in your data analysis?
Response From H. Petrowsky (Zurich, Switzerland):
Thank you, Thomas for your valuable comments on kinetic
growth. We analyzed various volume variables but they did not come
out as independent predictors. I also would like to make the point for
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the community that kinetic growth can be only uniformly used if the
volume scan is done for every patient at the same time. What we see
in the registry is that there is a wide variation on the reported date of
performing volume scans, for instance 40, 10, 8 days, and so on. If
volume gain is divided by these time periods, you might get not the
true growth rate knowing that there is no linear relationship over the
entire period. Therefore, we have to be careful to use data on the
kinetic growth rate. I think that this variable has to be completely
controlled within a group and within a project. The registry will not
provide this set of data.
In terms of technical evolution with partial ALPPS and
ALPPS, you are right. We included partial transection variant to
which we completely switched in Zurich in our analysis. At our
center, we have good experiences with having a less invasive concept
to do this procedure.We also looked at our current analysis but partial
ALPPS or other variants did not come out as significant predictors.
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